Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Nihon Hinyokika Gakkai Zasshi ; 83(3): 348-51, 1992 Mar.
Article in Japanese | MEDLINE | ID: mdl-1532997

ABSTRACT

The case is a 45-year-old female who underwent right total nephroureterectomy and partial cystectomy for renal pelvic cancer. During the operation, she received blood transfusion. On the 10th postoperative day, she developed high fever and skin rush on the face, which were followed by liver dysfunction and pancytopenia. On the 18th post-operative day, she died of sepsis. Autopsy revealed hypoplasia and aplasia of the bone marrow and severe atrophy of the systemic lymph nodes and spleen. The characteristic clinical course and autopsy findings of this case closely resembled graft-versus-host disease which is observed after bone marrow transplantation or blood transfusion given to patients with severe immunodeficiency. It is therefore strongly suggested that postoperative erythroderma of this case was induced by graft-versus-host reaction due to blood transfusion given during the operation.


Subject(s)
Dermatitis, Exfoliative/pathology , Graft vs Host Reaction , Nephrectomy , Postoperative Complications , Transfusion Reaction , Ureter/surgery , Dermatitis, Exfoliative/etiology , Female , Humans , Kidney Neoplasms/surgery , Kidney Pelvis , Middle Aged
2.
Hinyokika Kiyo ; 30(4): 537-43, 1984 Apr.
Article in Japanese | MEDLINE | ID: mdl-6207714

ABSTRACT

Forty-three patients with benign prostatic hyperplasia were treated with weekly i.m. injections of 400 mg oxendolone for 12 weeks. The subjective symptoms were improved in 83% of these patients. Residual urine was decreased significantly and Qmax was increased by this treatment. Serum VLDL level was suppressed significantly, whereas the levels of LDL, total cholesterol, HDL-cholesterol and triglycerides were changed little. Atherosclerotic index and the ratio of (total cholesterol--HDL-cholesterol) to (HDL-cholesterol), was not influenced by the treatment. No severe side-effect was found. These findings suggest that oxendolone is the drug of choice for non-surgical treatment of benign prostatic hyperplasia.


Subject(s)
Androgen Antagonists/therapeutic use , Lipids/blood , Lipoproteins/blood , Nandrolone/analogs & derivatives , Prostatic Hyperplasia/drug therapy , Aged , Drug Evaluation , Humans , Male , Middle Aged , Nandrolone/therapeutic use , Prostatic Hyperplasia/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...